Ropivacaine Hydrochloride Injection recalled; manufacturer unable to complete stability studies
Akorn, Inc. recalls all lots of Ropivacaine Hydrochloride Injection nationwide because the manufacturer went out of business and cannot complete required stability studies.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of an injectable drug with unverified stability. Although no illnesses or injuries have been reported, an injectable medication where the manufacturer cannot complete required stability studies to verify safety and effectiveness represents a risk-of-harm situation justifying High severity.
Plain-English summary
Akorn, Inc. is recalling all lots of Ropivacaine Hydrochloride Injection USP 0.2%, an injectable pharmaceutical supplied in 100 mL vials.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. The manufacturer went out of business and could no longer continue the stability studies required by the FDA. These studies are necessary to verify that the product maintains its safety and effectiveness throughout its shelf life.
The affected product was distributed nationwide in the United States and Puerto Rico, and all manufacturing lots are included in the recall.
The recalled product
- Product
- Ropivacaine Hydrochloride Injection USP, 0.2%, 200mg/100 mL (2 mg/mL), 100 mL Vial, Rx Only, Manufactured by: Akorn Inc., Lake Forest, IL 60045. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Injectable Drug
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 86 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · stability unverified
See all →- HighFluticasone Propionate Nasal Spray Recalled Due to Manufacturing Quality Concerns
FDA (Drugs) · 2023-06-07
- ModerateAkorn Recalls Cromolyn Sodium Ophthalmic Solution Over Stability Studies
FDA (Drugs) · 2023-06-07
- ModerateFerrous Sulfate Iron Supplement Drops Recalled for Manufacturing Stability Issues
FDA (Drugs) · 2023-06-07
- HighTrihexyphenidyl Hydrochloride Oral Solution Recalled for Unverified Stability
FDA (Drugs) · 2023-06-07
- HighNeomycin and Polymyxin B Eye Ointment Recalled for Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
Similar recalls
- ModerateAkorn Recalls Rifampin for Injection Due to Impurity Specification Failure
FDA (Drugs) · 2014-10-01
- LowAkorn Recalls RIFAMPIN FOR INJECTION Due to Impurity Specifications
FDA (Drugs) · 2015-11-25
- HighLidocaine Hydrochloride Jelly Recalled Due to cGMP Deviations and Turbidity
FDA (Drugs) · 2022-09-14
- ModerateDrug recall: Proparacaine eye solution due to manufacturing deviations
FDA (Drugs) · 2023-01-25
- ModerateLidocaine Hydrochloride Jelly Recalled for Manufacturing Quality Deviations
FDA (Drugs) · 2023-01-25
- ModerateCiprofloxacin ophthalmic solution recalled for manufacturing practice deviations
FDA (Drugs) · 2023-01-25